Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]AZD4831 Mass Balance Study
NCT04407091Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitiperstat in heart failure (HF) and cardiovascular diseases (CVD), sponsored by AstraZeneca. Primary endpoints: Cumulative amount of AZD4831 excreted at 336 hours, Cumulative percentage of dose excreted at 336 hours and 1 more. Started Jun 2020; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure (HF)cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT04407091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407091.